Karyopharm Therapeutics (KPTI) Finished Goods (2019 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Finished Goods came in at $430000.0 in Q4 2025, down 9.85% YoY from $477000.0 in Q4 2024, and down 0.69% on a QoQ basis from $433000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Finished Goods (2019 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Finished Goods data on file, last reported at $430000.0 in Q4 2025.
- Quarterly Finished Goods fell 9.85% year-over-year to $430000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $430000.0 (down 9.85% YoY) and the FY2025 annual result came in at $430000.0, down 9.85% from the prior year.
- Finished Goods fell to $430000.0 in Q4 2025, from $433000.0 in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $991000.0 in Q3 2022 to a low of $114000.0 in Q1 2021.
- A 5-year average of $547600.0 and a median of $455000.0 in 2024 frame the typical range for Finished Goods.
- Annual changes were most pronounced in 2021 — Finished Goods jumped 424.05% — and 2025, when it slumped 44.02%.
- Tracing KPTI's Finished Goods over 5 years: stood at $414000.0 in 2021, then soared by 135.75% to $976000.0 in 2022, then declined by 22.34% to $758000.0 in 2023, then plunged by 37.07% to $477000.0 in 2024, then decreased by 9.85% to $430000.0 in 2025.
- The last three Finished Goods figures came in at $430000.0 (Q4 2025), $433000.0 (Q3 2025), and $349000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 199,000.00 |
| Dec 31, 2025 | 430,000.00 |
| Sep 30, 2025 | 433,000.00 |
| Jun 30, 2025 | 349,000.00 |
| Mar 31, 2025 | 351,000.00 |
| Dec 31, 2024 | 477,000.00 |
| Sep 30, 2024 | 542,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Mar 31, 2024 | 627,000.00 |
| Dec 31, 2023 | 758,000.00 |
| Sep 30, 2023 | 759,000.00 |
| Jun 30, 2023 | 848,000.00 |
| Mar 31, 2023 | 936,000.00 |
| Dec 31, 2022 | 976,000.00 |
| Sep 30, 2022 | 991,000.00 |
| Jun 30, 2022 | 343,000.00 |
| Mar 31, 2022 | 385,000.00 |
| Dec 31, 2021 | 414,000.00 |
| Sep 30, 2021 | 398,000.00 |
| Jun 30, 2021 | 223,000.00 |